Literature DB >> 31656042

The association of the optimal bolus of dexmedetomidine with its favourable haemodynamic outcomes in adult surgical patients under general anaesthesia.

Cheng-Yu Wang1,2, Fang Chen1,2, Junzheng Wu3, Shu-Ying Fu1,2, Xi-Mou Xu1,2, Jia Chen1,2, Yi-Fei Jiang1,2, Qingquan Lian1,2, Hua-Cheng Liu1,2.   

Abstract

AIMS: Dexmedetomidine is highly specific α2-adrenoceptor agonist. A single bolus of dexmedetomidine can achieve clinical therapeutic effect. Therefore, it is essential to know the safety margin between the clinical effectiveness dosages of dexmedetomidine and its side effect.
METHODS: A total of 42 patients who underwent elective thyroidectomy were enrolled in this study. Dexmedetomidine was given as a single bolus injection 30 min towards the end of surgery. The up-and-down sequential schedule was used in this study. The starting dose of dexmedetomidine was set at 0.1 μg/kg in the first patient and the next patient would then receive a dose of dexmedetomidine decremented by 0.05 μg/kg if the prior patient's baseline heart rate (HR) had a decrease of ≥20% and/or mean arterial blood pressure (MAP) increase or decrease of ≥20%, otherwise, the following patient would receive an incremental 0.05 μg/kg dose of dexmedetomidine. The analytic techniques of linear, linear-logarithmic, exponential regressions and centred isotonic regression were used to determine the ED50 of dexmedetomidine and the residual standard errors were calculated for the comparison of goodness of fit among the different models.
RESULTS: The median (interquartile range [range]) lowest HR was 57 beats/min (53-63.3[46-76]) with an average HR decrease of 8.0 beats/min (5-13 [4 to 23]). The median (interquartile range [range]) highest MAP was 98 mmHg (91.8-105 [83-126]) with a MAP increase of 10.0 mmHg (6.8-18.0 [2-24]). The ED50 (95% confidence interval) from 4 different statistical approaches (linear, linear-logarithmic, exponential regressions and centred isotonic regression) were 0.262 μg/kg (0.243, 0.306), 0.252 μg/kg (0.238, 0.307), 0.283 μg/kg (0.238, 0.307), and 0.278 μg/kg, respectively. Among the 4 models, the exponential regression had the least residual standard error (0.03618).
CONCLUSION: The ED50 derived from 4 statistical models for an intravenous bolus of dexmedetomidine without significant haemodynamic effects was distributed in a narrow range of 0.252-0.283 μg/kg, and the exponential regression was the model to best match the study data.
© 2019 The British Pharmacological Society.

Entities:  

Keywords:  adult; dexmedetomidine; general anaesthesia; haemodynamic

Mesh:

Substances:

Year:  2019        PMID: 31656042      PMCID: PMC6983508          DOI: 10.1111/bcp.14137

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

1.  Dexmedetomidine hemodynamics in children after cardiac surgery.

Authors:  Amanda L Potts; Brian J Anderson; Nick H G Holford; Thuy C Vu; Guy R Warman
Journal:  Paediatr Anaesth       Date:  2010-03-11       Impact factor: 2.556

Review 2.  Advances in and limitations of up-and-down methodology: a précis of clinical use, study design, and dose estimation in anesthesia research.

Authors:  Nathan L Pace; Mario P Stylianou
Journal:  Anesthesiology       Date:  2007-07       Impact factor: 7.892

3.  The continual reassessment method for dose-finding studies: a tutorial.

Authors:  Elizabeth Garrett-Mayer
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

4.  Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers.

Authors:  Yung-Wei Hsu; Luis I Cortinez; Kerri M Robertson; John C Keifer; Sam T Sum-Ping; Eugene W Moretti; Christopher C Young; David R Wright; David B Macleod; Jacques Somma
Journal:  Anesthesiology       Date:  2004-11       Impact factor: 7.892

5.  Effects of fentanyl-lidocaine-propofol and dexmedetomidine-lidocaine-propofol on tracheal intubation without use of muscle relaxants.

Authors:  Volkan Hanci; Gülay Erdoğan; Rahşan Dilek Okyay; Bülent Serhan Yurtlu; Hilal Ayoğlu; Yunus Baydilek; Işil Ozkoçak Turan
Journal:  Kaohsiung J Med Sci       Date:  2010-05       Impact factor: 2.744

6.  The effects of preanesthetic, single-dose dexmedetomidine on induction, hemodynamic, and cardiovascular parameters.

Authors:  Hülya Basar; Serpil Akpinar; Nur Doganci; Unase Buyukkocak; Cetin Kaymak; Ozgur Sert; Alpaslan Apan
Journal:  J Clin Anesth       Date:  2008-09       Impact factor: 9.452

7.  The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects.

Authors:  Laura E Nelson; Jun Lu; Tianzhi Guo; Clifford B Saper; Nicholas P Franks; Mervyn Maze
Journal:  Anesthesiology       Date:  2003-02       Impact factor: 7.892

8.  Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes.

Authors:  B C Bloor; D S Ward; J P Belleville; M Maze
Journal:  Anesthesiology       Date:  1992-12       Impact factor: 7.892

9.  The association of the optimal bolus of dexmedetomidine with its favourable haemodynamic outcomes in adult surgical patients under general anaesthesia.

Authors:  Cheng-Yu Wang; Fang Chen; Junzheng Wu; Shu-Ying Fu; Xi-Mou Xu; Jia Chen; Yi-Fei Jiang; Qingquan Lian; Hua-Cheng Liu
Journal:  Br J Clin Pharmacol       Date:  2019-12-12       Impact factor: 4.335

Review 10.  Different types of centrally acting antihypertensives and their targets in the central nervous system.

Authors:  P A van Zwieten; J P Chalmers
Journal:  Cardiovasc Drugs Ther       Date:  1994-12       Impact factor: 3.727

View more
  1 in total

1.  The association of the optimal bolus of dexmedetomidine with its favourable haemodynamic outcomes in adult surgical patients under general anaesthesia.

Authors:  Cheng-Yu Wang; Fang Chen; Junzheng Wu; Shu-Ying Fu; Xi-Mou Xu; Jia Chen; Yi-Fei Jiang; Qingquan Lian; Hua-Cheng Liu
Journal:  Br J Clin Pharmacol       Date:  2019-12-12       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.